Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 97(24): 13063-8, 2000 Nov 21.
Article in English | MEDLINE | ID: mdl-11087860

ABSTRACT

Retroviral Gag polyproteins have specific regions, commonly referred to as late assembly (L) domains, which are required for the efficient separation of assembled virions from the host cell. The L domain of HIV-1 is in the C-terminal p6(gag) domain and contains an essential P(T/S)AP core motif that is widely conserved among lentiviruses. In contrast, the L domains of oncoretroviruses such as Rous sarcoma virus (RSV) have a more N-terminal location and a PPxY core motif. In the present study, we used chimeric Gag constructs to probe for L domain activity, and observed that the unrelated L domains of RSV and HIV-1 both induced the appearance of Gag-ubiquitin conjugates in virus-like particles (VLP). Furthermore, a single-amino acid substitution that abolished the activity of the RSV L domain in VLP release also abrogated its ability to induce Gag ubiquitination. Particularly robust Gag ubiquitination and enhancement of VLP release were observed in the presence of the candidate L domain of Ebola virus, which contains overlapping P(T/S)AP and PPxY motifs. The release defect of a minimal Gag construct could also be corrected through the attachment of a peptide that serves as a physiological docking site for the ubiquitin ligase Nedd4. Furthermore, VLP formation by a full-length Gag polyprotein was sensitive to lactacystin, which depletes the levels of free ubiquitin through inhibition of the proteasome. Our findings suggest that the engagement of the ubiquitin conjugation machinery by L domains plays a crucial role in the release of a diverse group of enveloped viruses.


Subject(s)
Avian Sarcoma Viruses/physiology , Ebolavirus/physiology , Gene Products, gag/metabolism , HIV-1/physiology , Ligases/metabolism , Virus Replication/physiology , Amino Acid Sequence , Conserved Sequence , Gene Products, gag/chemistry , HeLa Cells , Humans , Molecular Sequence Data , Recombinant Proteins/metabolism , Sequence Alignment , Sequence Homology, Amino Acid , Transfection , Ubiquitin-Protein Ligases , Ubiquitins/metabolism , Virion/physiology
2.
J Virol ; 74(13): 6198-202, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10846106

ABSTRACT

Mature human immunodeficiency virus type 1 (HIV-1) virions contain a typically cone-shaped core that encases the viral genome. In this study, we established conditions which allowed the efficient isolation of morphologically intact HIV-1 cores from virions. The isolated cores consisted mostly of cones which appeared uniformly capped at both ends but were heterogeneous with respect to the shape of the broad cap as well as the dimensions and angle of the cone. Vpr, a nonstructural virion component implicated in the nuclear import of the viral genome, was recovered in core preparations of HIV-1 and simian immunodeficiency viruses from African green monkeys. Unexpectedly, p6(gag), a structural protein required for the incorporation of Vpr, was absent from HIV-1 core preparations. Taken together, our results indicate that the incorporation of Vpr into the virion core is a conserved feature of primate lentiviruses and that the interactions required for the uptake of Vpr into assembling particles differ from those which confine Vpr within the core.


Subject(s)
Gene Products, gag/metabolism , Gene Products, vpr/metabolism , HIV-1/metabolism , Animals , Capsid/drug effects , Capsid/ultrastructure , Cell Line, Transformed , Detergents/pharmacology , HIV-1/drug effects , HIV-1/isolation & purification , HIV-1/ultrastructure , Humans , Nucleocapsid/drug effects , Nucleocapsid/ultrastructure , Peptidylprolyl Isomerase/metabolism , Polyethylene Glycols/pharmacology , Simian Immunodeficiency Virus/isolation & purification , Simian Immunodeficiency Virus/metabolism , Viral Core Proteins/drug effects , Viral Core Proteins/isolation & purification , Viral Core Proteins/metabolism , Viral Core Proteins/ultrastructure , gag Gene Products, Human Immunodeficiency Virus , vpr Gene Products, Human Immunodeficiency Virus
3.
J Virol ; 74(12): 5395-402, 2000 Jun.
Article in English | MEDLINE | ID: mdl-10823843

ABSTRACT

The human immunodeficiency virus type 1 (HIV-1) Gag precursor Pr55(gag) by itself is capable of assembling into retrovirus-like particles (VLP). In the present study, we attempted to identify the minimal Gag sequences required for the formation of VLP. Our results show that about 80% of Pr55(gag) can be either deleted or replaced by heterologous sequences without significantly compromising VLP production. The smallest chimeric molecule still able to efficiently form VLP was only about 16 kDa. This minimal Gag construct contained the leucine zipper domain of the yeast transcription factor GCN4 to substitute for the assembly function of nucleocapsid (NC), followed by a P-P-P-P-Y motif to provide late budding (L) domain function, and retained only the myristylation signal and the C-terminal capsid-p2 domain of Pr55(gag). We also show that the L domain function of HIV-1 p6(gag) is not dependent on the presence of an active viral protease and that the NC domain of Pr55(gag) is dispensable for the incorporation of Vpr into VLP.


Subject(s)
DNA-Binding Proteins , Gene Products, gag/chemistry , Gene Products, gag/metabolism , HIV-1/physiology , Peptide Fragments/chemistry , Peptide Fragments/metabolism , Protein Precursors/chemistry , Protein Precursors/metabolism , Saccharomyces cerevisiae Proteins , Virus Assembly , Amino Acid Motifs , Amino Acid Sequence , Centrifugation, Density Gradient , Dimerization , Fungal Proteins/chemistry , Fungal Proteins/genetics , Fungal Proteins/metabolism , Gene Deletion , Gene Products, gag/genetics , Gene Products, vpr/metabolism , HIV Protease/genetics , HIV Protease/metabolism , HIV-1/chemistry , HIV-1/genetics , HeLa Cells , Human Immunodeficiency Virus Proteins , Humans , Leucine Zippers , Molecular Weight , Myristic Acid/metabolism , Peptide Fragments/genetics , Protein Binding , Protein Kinases/chemistry , Protein Kinases/genetics , Protein Kinases/metabolism , Protein Precursors/genetics , Protein Structure, Tertiary , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Structure-Activity Relationship , Time Factors , Viral Regulatory and Accessory Proteins/genetics , Viral Regulatory and Accessory Proteins/metabolism , gag Gene Products, Human Immunodeficiency Virus , vpr Gene Products, Human Immunodeficiency Virus
4.
J Virol ; 73(12): 9992-9, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10559313

ABSTRACT

Vpr is a small accessory protein of human and simian immunodeficiency viruses (HIV and SIV) that is specifically incorporated into virions. Members of the HIV-2/SIV(sm)/SIV(mac) lineage of primate lentiviruses also incorporate a related protein designated Vpx. We previously identified a highly conserved L-X-X-L-F sequence near the C terminus of the p6 domain of the Gag precursor as the major virion association motif for HIV-1 Vpr. In the present study, we show that a different leucine-containing motif (D-X-A-X-X-L-L) in the N-terminal half of p6(gag) is required for the incorporation of SIV(mac) Vpx. Similarly, the uptake of SIV(mac) Vpr depended primarily on the D-X-A-X-X-L-L motif. SIV(mac) Vpr was unstable when expressed alone, but its intracellular steady-state levels increased significantly in the presence of wild-type Gag or of the proteasome inhibitor lactacystin. Collectively, our results indicate that the interaction with the Gag precursor via the D-X-A-X-X-L-L motif diverts SIV(mac) Vpr away from the proteasome-degradative pathway. While absent from HIV-1 p6(gag), the D-X-A-X-X-L-L motif is conserved in both the HIV-2/SIV(sm)/SIV(mac) and SIV(agm) lineages of primate lentiviruses. We found that the incorporation of SIV(agm) Vpr, like that of SIV(mac) Vpx, is absolutely dependent on the D-X-A-X-X-L-L motif, while the L-X-X-L-F motif used by HIV-1 Vpr is dispensable. The similar requirements for the incorporation of SIV(mac) Vpx and SIV(agm) Vpr provide support for their proposed common ancestry.


Subject(s)
Conserved Sequence , Gene Products, gag/metabolism , Gene Products, vpr/metabolism , Leucine , Simian Immunodeficiency Virus/physiology , Viral Regulatory and Accessory Proteins/metabolism , Virus Assembly , Amino Acid Sequence , Animals , Gene Products, gag/genetics , Gene Products, vpr/genetics , HeLa Cells , Humans , Intracellular Fluid , Viral Regulatory and Accessory Proteins/genetics , Virion , gag Gene Products, Human Immunodeficiency Virus
5.
J Virol ; 72(3): 2072-8, 1998 Mar.
Article in English | MEDLINE | ID: mdl-9499062

ABSTRACT

The capsid (CA) and nucleocapsid domains of the human immunodeficiency virus type 1 Gag polyprotein are separated by the p2 spacer peptide, which is essential for virus replication. Previous studies have revealed that p2 has an important role in virus morphogenesis. In this paper, we show that a crucial assembly determinant maps to the highly conserved N terminus of p2, which is predicted to form part of an alpha-helix that begins in CA. A mutational analysis indicates that the ability of the N terminus of p2 to adopt an alpha-helical structure is essential for its function during virus assembly. To prevent CA-p2 processing, it was necessary to mutate both the CA-p2 cleavage site and an internal cleavage site within p2. Virions produced by the double mutant lacked a conical core shell and instead contained a thin electron-dense shell about 10 nm underneath the virion membrane. These results suggest that p2 is transiently required for proper assembly, but needs to be removed from the C terminus of CA to weaken CA-CA interactions and allow the rearrangement of the virion core shell during virus maturation.


Subject(s)
Gene Products, gag/chemistry , Gene Products, gag/metabolism , HIV-1/physiology , Peptide Fragments/metabolism , Protein Conformation , Protein Precursors/chemistry , Protein Precursors/metabolism , Virus Assembly , Amino Acid Sequence , Capsid , Chromosome Mapping , Conserved Sequence , Gene Products, gag/genetics , HIV-1/genetics , HIV-1/ultrastructure , HeLa Cells , Humans , Jurkat Cells , Molecular Sequence Data , Mutagenesis , Peptide Fragments/chemistry , Peptide Fragments/genetics , Protein Precursors/genetics , Structure-Activity Relationship , Virion/ultrastructure , gag Gene Products, Human Immunodeficiency Virus
6.
Proc Natl Acad Sci U S A ; 94(20): 10943-8, 1997 Sep 30.
Article in English | MEDLINE | ID: mdl-9380739

ABSTRACT

HIV-1 specifically incorporates the peptidyl prolyl isomerase cyclophilin A (CyPA), the cytosolic receptor for the immunosuppressant cyclosporin A (CsA). HIV-1 replication is inhibited by CsA as well as by nonimmunosuppressive CsA analogues that bind to CyPA and interfere with its virion association. In contrast, the related simian immunodeficiency virus SIVmac, which does not interact with CyPA, is resistant to these compounds. The incorporation of CyPA into HIV-1 virions is mediated by a specific interaction between the active site of the enzyme and the capsid (CA) domain of the HIV-1 Gag polyprotein. We report here that the transfer of HIV-1 CA residues 86-93, which form part of an exposed loop, to the corresponding position in SIVmac resulted in the efficient incorporation of CyPA and conferred an HIV-1-like sensitivity to a nonimmunosuppressive cyclosporin. HIV-1 CA residues 86-90 were also sufficient to transfer the ability to efficiently incorporate CyPA, provided that the length of the CyPA-binding loop was preserved. However, the resulting SIVmac mutant required the presence of cyclosporin for efficient virus replication. The results indicate that the presence or absence of a type II tight turn adjacent to the primary CyPA-binding site determines whether CyPA incorporation enhances or inhibits viral replication. By demonstrating that CyPA-binding-site residues can induce cyclosporin sensitivity in a heterologous context, this study provides direct in vivo evidence that the exposed loop between helices IV and V of HIV-1 CA not merely constitutes a docking site for CyPA but is a functional target of this cellular protein.


Subject(s)
Cyclosporine/pharmacology , HIV-1/metabolism , Peptidylprolyl Isomerase/metabolism , Simian Immunodeficiency Virus/metabolism , Animals , Binding Sites , Cell Line , HIV-1/physiology , HeLa Cells , Humans , Macaca mulatta , Mutagenesis , Peptidylprolyl Isomerase/genetics , Virus Replication
SELECTION OF CITATIONS
SEARCH DETAIL
...